DNTH Stock Forecast & Price Target

Dianthus Therapeutics is a clinical-stage biotechnology company with a positive outlook, based on the company's strong pipeline and experienced leadership team. Their focus on creating revolutionary treatments for severe autoimmune diseases, including their internally developed DNTH312 targeting validated pathways and offering IP protection through 2047, could lead to potential approval and significant market potential. With their financials showing a net present value of $10.7B and a 12-month price target of $158, we maintain our Buy rating and believe DNTH is well-positioned in a competitive market with a differentiated profile.

Dianthus Therapeutics is facing significant challenges and uncertainties in its path to commercialization and profitability. Despite its strong management team and promising pipeline, the company is not expected to generate significant revenue in the near future, with only $0.5M reported in 1Q26. Additionally, the recent $719M secondary offering may not provide enough cash runway, as the company estimates only enough funding until 2030.